US2021139540A1PendingUtilityA1
Multivalent ligand-lipid constructs

Assignee: BOVIN NICOLAI VLADIMIROVICHPriority: Nov 21, 2014Filed: Sep 21, 2020Published: May 13, 2021
Est. expiryNov 21, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:Nicolai Bovin Stephen Micheal Henry Elena Korchagina Igor Leonidovich Rodionov Alexander Borisovich Tuzikov
A61K 31/685C07K 14/001C07K 9/00C07K 7/08C07K 7/06A61P 35/00A61K 47/555A61K 38/00A61K 31/702A61K 31/7016A61K 31/7004
PatentIndex Score
Cited by
References
Claims
Abstract

Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method of treating patients with tumours by intratumoural injection of a composition comprising at least one multivalent ligand-lipid construct of the structure: 
       
         
           
           
               
               
           
         
         where F is an aminoalkylglycoside or an oligopeptide comprising an N-maleoyl-β-alanine conjugated Cys residue, L is a conjugated phosphatidylethanolamide, and S is a tetraantennary spacer of the structure: 
       
       
         
           
           
               
               
           
         
         where m is the integer 1, 2 or 3 and R is of the structure: 
       
       
         
           
           
               
               
           
         
         where M is a monovalent cation or substituent, n is the integer 2, 3, 4, 5, 6 or 7, and * is the point of attachment of F or L. 
       
     
     
         3 . The method of  claim 2  where the conjugated phosphatidylethanolamide is of the structure: 
       
         
           
           
               
               
           
         
         where p is the integer 3, 4 or 5, W1 and W2 are independently selected from C16-20-alkyl or mono- or di-unsaturated C16-20-alkenyl groups and * is the point of attachment of S. 
       
     
     
         4 . The method of  claim 3  where F is an aminoalkylglycoside and the at least one multivalent ligand-lipid construct is of the structure: 
       
         
           
           
               
               
           
         
       
       where Glyc is a glycan and q and r are integers independently selected from 1, 2, 3 and 4. 
     
     
         5 . The method of  claim 4  where Glyc is a glycan selected from the group consisting of: (Neu5Acα6Galβ4GlcNAcβ2Manα) 2 3,6Manβ4GlcNAcβ4GlcNAcβ (YDS); Fucα2Galβ(H di ); Fucα2Galβ3(Fucα4)GlcNAcβ (Le b ); Fucα2Galβ3GlcNAcβ3Galβ4Glcβ (LNFP I); Fucα2Galβ4(Fucα3)GlcNAcβ (Le y ); Fucα2Galβ4GlcNAcβ (H2); Galα; Galβ1-3(Fucα1-3)GlcNAc; Galβ1-3(Fucα1-4)GlcNAcβ1-4GlcNAc; Galβ1-3GlcNAcβ1-4GlcNAc; Galβ1-3GlcNAc; Galβ1-4(Fucα1-3)GlcNAcβ1-4GlcNAc; Galβ1-4(Fucα1-3)GlcNAc; Galβ1-4GlcNAcβ1-4GlcNAc; Galβ1-4GlcNAc; Galα3(Fucα2)Galβ(B tri ); Galα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (Ble b ); Galα3(Fucα2)Galβ3GalNAcα (B3); Galα3(Fucα2)Galβ3GalNAcβ (B4); Galα3(Fucα2)Galβ3GlcNAcβ (B1); Galα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (Ble y ); Galα3(Fucα2)Galβ4GlcNAcβ (B2); Galα3Galβ4GlcNAcβ (Galili); Galα4Galβ4GlcNAcβ (P 1 ); Galα4Galβ4Glcβ (Gb3 (P k )); Galα4GlcNAcβ (α-LN); GalNAcα3(Fucα2)Galβ(A tri ); GalNAcα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (ALe b ); GalNAcα3(Fucα2)Galβ3GalNAcα (A3); GalNAcα3(Fucα2)Galβ3GalNAcβ (A4); GalNAcα3(Fucα2)Galβ3GlcNAcβ (A1); GalNAcα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (ALe y ); GalNAcα3(Fucα2)Galβ4GlcNAcβ (A2); GalNAcα3GalNAcβ (Fs2); GalNAcα3GalNAcβ3Galα4Galβ4Glcβ (Fs5); GalNAcα3Galβ(A di ); GalNAcα3Galβ4GlcNAcβ; GalNAcβ; GalNAcβ3Galα4Galβ4Glcβ (P); GalNH 2 α3(Fucα2)Galβ (AcqB); Galβ; Galβ3(Fucα4)GlcNAcβ (Le a ); Galβ3GalNAcα (TF); Galβ3GalNAcβ4Galβ4Glcβ (GA1); Galβ4(Fucα3)GlcNAcβ (Le x ); Galβ4GlcNAcβ3Galβ4GlcNAcβ (i(LN 2 )); Galβ4GlcNAcβ3Galβ4Glcβ (LNnT); Galβ4Glcβ (Lac); GlcAβ3[GlcNAcβ4Glcβ3] n GlcNAc-aminoalditol (hyaluronate); Manα6(Manα3)Manβ (Man 3 ); Neu5Acα3Galβ4GlcNAcβ (Neu5Ac3′LN); Neu5Acα3Galβ4Glcβ (Neu5Ac3′Lac); Neu5Acα6GalNAcαβ (SiaTn); Neu5Acα6Galβ4GlcNAcβ (Neu5Ac6′LN); Neu5Gcα3Galβ4GlcNAcβ (Neu5Gc3′LN); SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAβ2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-4Gal; SAα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-3Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-3GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-3GlcNAc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-4Gal; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-3Galβ1-4GlcNAcβ1-4GlcNAc; SAα2-3Galβ1-4GlcNAc; SAα2-6Galβ1-3(Fucα1-4(GlcNAc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-3GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc; SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc; SAα2-6Galβ1-4GlcNAcβ1-4GlcNAc; SAα2-6Galβ1-4GlcNAc; SAα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-3Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc; SAα2-6Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc and SAα2-6Galβ1-4GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAc. 
     
     
         6 . The method of  claim 5  where Glyc is a glycan selected from the group consisting of: (Neu5Acα6Galβ4GlcNAcβ2Manα) 2 3,6Manβ4GlcNAcβ4GlcNAcβ (YDS); Fucα2Galβ(H di ); Fucα2Galβ3(Fucα4)GlcNAcβ (Le b ); Fucα2Galβ3GlcNAcβ3Galβ4Glcβ (LNFP I); Fucα2Galβ4(Fucα3)GlcNAcβ (Le y ); Fucα2Galβ4GlcNAcβ (H2); Galα; Galα3(Fucα2)Galβ(B tri ); Galα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (Ble b ); Galα3(Fucα2)Galβ3GalNAcα (B3); Galα3(Fucα2)Galβ3GalNAcβ (B4); Galα3(Fucα2)Galβ3GlcNAcβ (B1); Galα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (Ble y ); Galα3(Fucα2)Galβ4GlcNAcβ (B2); Galα3Galβ4GlcNAcβ (Galili); Galα4Galβ4GlcNAcβ (P 1 ); Galα4Galβ4Glcβ (Gb3 (P k )); Galα4GlcNAcβ (α-LN); GalNAcα3(Fucα2)Galβ(A tri ); GalNAcα3(Fucα2)Galβ3(Fucα4)GlcNAcβ (ALe b ); GalNAcα3(Fucα2)Galβ3GalNAcα (A3); GalNAcα3(Fucα2)Galβ3GalNAcβ (A4); GalNAcα3(Fucα2)Galβ3GlcNAcβ (A1); GalNAcα3(Fucα2)Galβ4(Fucα3)GlcNAcβ (ALe y ); GalNAcα3(Fucα2)Galβ4GlcNAcβ (A2); GalNAcα3GalNAcβ (Fs2); GalNAcα3GalNAcβ3Galα4Galβ4Glcβ (Fs5); GalNAcα3Galβ(A di ); GalNAcα3Galβ4GlcNAcβ; GalNAcβ; GalNAcβ3Galα4Galβ4Glcβ (P); GalNH 2 α3(Fucα2)Galβ (AcqB); Galβ; Galβ3(Fucα4)GlcNAcβ (Le a ); Galβ3GalNAcα (TF); Galβ3GalNAcβ4Galβ4Glcβ (GA1); Galβ4(Fucα3)GlcNAcβ (Le x ); Galβ4GlcNAcβ3Galβ4GlcNAcβ (i(LN 2 )); Galβ4GlcNAcβ3Galβ4Glcβ (LNnT); Galβ4Glcβ (Lac); GlcAβ3[GlcNAcβ4GlcAβ3] n GlcNAc-aminoalditol (hyaluronate); Manα6(Manα3)Manβ (Man 3 ); Neu5Acα3Galβ4GlcNAcβ (Neu5Ac3′LN); Neu5Acα3Galβ4Glcβ (Neu5Ac3′Lac); Neu5Acα6GalNAcαβ (SiaTn); Neu5Acα6Galβ4GlcNAcβ (Neu5Ac6′LN) and Neu5Gcα3Galβ4GlcNAcβ (Neu5Gc3′LN). 
     
     
         7 . The method of  claim 6  where Glyc is a glycan selected from: Galα3Galβ4GlcNAcβ (Galili) and GalNAcα3Galβ4GlcNAcβ. 
     
     
         8 . The method of  claim 7  where n is the integer 5. 
     
     
         9 . The method of  claim 3  where F is an oligopeptide comprising an N-maleoyl-β-alanine conjugated Cys residue and the construct is of the structure: 
       
         
           
           
               
               
           
         
         where Xaa is any amino acid residue and i and j are independently either zero or integers the sum of which is in the range 5 to 30 inclusive. 
       
     
     
         10 . The method of  claim 9  where i is an integer in the range 5 to 30 inclusive and j is zero. 
     
     
         10 . The method of  claim 10  where n is the integer 5.
Join the waitlist — get patent alerts

Track US2021139540A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.